G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of relentless meetings, deadlines, and the like has returned. You knew this would happen, though, yes? This calls for a much-needed cup of stimulation. Our flavor today is vanilla macadamia nut, for those keeping track. Please do join us. Remember that no prescription is required. Meanwhile, here are some tidbits. Hope you have a smashing day and do keep in touch …

Pascal Soriot will remain chief executive at AstraZeneca, after all? Shortly after reports from Israel emerged that he agreed in principle to become chief executive at Teva Pharmaceuticals, a fresh round of reports surfaced late last week that he will host the next AstraZeneca investor call. His tenure at AstraZeneca has been marked by setbacks since he arrived in 2012 and laid out an ambitious growth plan, partly to fend off a takeover by Pfizer.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • While this quote sounds rather British – “It’s difficult to have a constructive conversation with government if you are suing them,” says one unnamed source. – it shows they are still a bit ‘Americanized.’ I would have expected “One must observe that it’s difficult to have …” Ah, well, still deftly put.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.